UroGen Pharma Ltd. is a pharmaceutical company based in the United States that focuses on developing innovative solutions for urothelial and specialty cancers. They have created RTGel reverse-thermal hydrogel technology that improves the effectiveness of existing drugs through sustained release. Their main products, Jelmyto for pyelocalyceal solution and UGN-102 for intravesical solution, are designed for non-surgical tumor ablation in non-muscle invasive urothelial cancer. They also have an immuno-uro-oncology pipeline that includes UGN-301, an anti-CTLA-4 antibody. The company operates at a medium risk level based on their ESG score of 29.8.